心脏淀粉样变性中细胞外容积定量与CT心肌灌注分析的诊断价值
前瞻性研究纳入84例心脏淀粉样变性、43例非淀粉样心肌肥厚及33例无肥厚受试者,行全心动周期动态CT灌注成像。心脏淀粉样变性组CT测得细胞外容积高于非淀粉样心肌肥厚组和无肥厚组,心肌血容量和心肌血流量低于后两组;细胞外容积及部分灌注参数可预测死亡。
要点
- 心脏淀粉样变性患者CT细胞外容积升高(均值54.7%),高于非淀粉样心肌肥厚(34.6%)和无肥厚(35.9%)。
- 心脏淀粉样变性患者心肌血容量和心肌血流量低于非淀粉样心肌肥厚及无肥厚组。
- CT细胞外容积和灌注参数(平均斜率、达峰时间)可预测心脏淀粉样变性患者死亡。
核心结论
- 心脏淀粉样变性患者CT细胞外容积升高且CT灌注参数异常,细胞外容积和部分灌注参数可预测死亡。
研究设计与样本
- 前瞻性研究,纳入84例心脏淀粉样变性、43例非淀粉样心肌肥厚和33例无肥厚受试者,2017年4月至2018年12月间行全心动周期动态CT灌注成像;心脏淀粉样变性确诊依据阳性骨闪烁显像或心内膜心肌活检。
关键影像表现/征象
- 心脏淀粉样变性组CT细胞外容积均值54.7%±9.7,高于非淀粉样心肌肥厚组34.6%±9.1(P<.001)和无肥厚组35.9%±9.9(P=.001)。
- 心脏淀粉样变性组心肌血容量均值4.05 mL/100 g心肌±0.80,低于非淀粉样心肌肥厚组5.38 mL/100 g心肌±1.20(P<.001)和无肥厚组5.68 mL/100 g心肌±1.05(P<.001)。
- 心脏淀粉样变性组心肌血流量均值73.2 mL/100 g心肌每分钟±25.7,低于非淀粉样心肌肥厚组89.6 mL/100 g心肌每分钟±31.3(P=.007)和无肥厚组106.3 mL/100 g心肌每分钟±29.8(P<.001)。
诊断标准与关键数值
- 心脏淀粉样变性确诊标准为骨闪烁显像阳性或心内膜心肌活检证实。
- CT细胞外容积>0.56 vs ≤0.56预测心脏淀粉样变性患者死亡的HR为4.2(95%CI:1.4,11.8)。
- 平均斜率≤3.0 sec⁻¹ vs >3.0 sec⁻¹预测死亡的HR为0.2(95%CI:0.1,0.8)。
- 达峰时间>20秒 vs ≤20秒预测死亡的HR为11.6(95%CI:1.3,101.6)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background CT can provide information regarding myocardial perfusion and expansion of the extracellular space, which is relevant to patients with cardiac amyloidosis (CA). Purpose To evaluate the role of CT in the diagnosis and prognosis of CA. Materials and Methods In this prospective study (Commission National de l'Informatique et des Libertés registration no. 1431858), participants with CA, participants with nonamyloid cardiac hypertrophy (NACH), and participants without hypertrophy were included between April 2017 and December 2018. The confirmed diagnosis of CA was determined according to established criteria (ie, proven with positive bone scintigraphy or endomyocardial biopsy). All participants were imaged with dynamic CT perfusion imaging at whole-heart cardiac CT. Extracellular volume measured at CT and myocardial perfusion parameters calculated on CT perfusion maps were compared among different participant groups. Differences between continuous data were tested using the unpaired t test, Mann-Whitney rank-sum test, or the Kruskal-Wallis test. Results A total of 84 participants with CA, 43 participants with NACH, and 33 participants without hypertrophy were included. Participants with CA exhibited a higher value of extracellular volume measured at CT (mean, 54.7% ± 9.7 [standard deviation]) than participants with NACH (mean, 34.6% ± 9.1; P < .001) and participants without hypertrophy (mean, 35.9% ± 9.9; P = .001). Mean myocardial blood volume and mean myocardial blood flow were lower in participants with CA (mean myocardial blood volume: 4.05 mL/100 g of myocardium ± 0.80; mean myocardial blood flow: 73.2 mL/100 g of myocardium per minute ± 25.7) compared to participants with NACH (mean myocardial blood volume: 5.38 mL/100 g of myocardium ± 1.20, P < .001; mean myocardial blood flow: 89.6 mL/100 g of myocardium per minute ± 31.3, P = .007) and participants without hypertrophy (mean myocardial blood volume: 5.68 mL/100 g of myocardium ± 1.05; mean myocardial blood flow: 106.3 mL/100 g of myocardium per minute ± 29.8; P < .001 for both). Extracellular volume measured at CT (hazard ratio >0.56 vs ≤0.56 = 4.2 [95% CI: 1.4, 11.8]), mean slope (hazard ratio ≤3.0 sec-1 vs >3.0 sec-1 = 0.2 [95% CI: 0.1, 0.8]), and time to peak (hazard ratio >20 seconds vs ≤20 seconds = 11.6 [95% CI: 1.3, 101.6]) were predictive of mortality in participants with CA. Conclusion Participants with cardiac amyloidosis exhibited an increase in extracellular volume at CT and abnormal CT perfusion parameters. Extracellular volume and several perfusion parameters were predictive of mortality. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Zimmerman in this issue.
引用
- Deux JF, Nouri R, Tacher V, et al. Diagnostic Value of Extracellular Volume Quantification and Myocardial Perfusion Analysis at CT in Cardiac Amyloidosis. Radiology. 2021. PMID: 34100681. doi:10.1148/radiol.2021204192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。